- Record: found
- Abstract: not found
- Article: not found
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
Emma Guttman-Yassky ,
Jonathan I. Silverberg ,
Osamu Nemoto ,
Seth B. Forman ,
August Wilke ,
Randy Prescilla ,
Amparo de la Peña ,
Fabio P. Nunes ,
Jonathan Janes ,
Margaret Gamalo ,
David Donley ,
Jim Paik ,
Amy M. DeLozier ,
Brian J. Nickoloff ,
Eric L. Simpson
February 2018
February 2018
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Baricitinib, an oral selective inhibitor of Janus kinase 1 and Janus kinase 2, modulates
proinflammatory cytokine signaling.